[go: up one dir, main page]

PE20142294A1 - Compuestos de indol e indazol que activan la ampk - Google Patents

Compuestos de indol e indazol que activan la ampk

Info

Publication number
PE20142294A1
PE20142294A1 PE2014001610A PE2014001610A PE20142294A1 PE 20142294 A1 PE20142294 A1 PE 20142294A1 PE 2014001610 A PE2014001610 A PE 2014001610A PE 2014001610 A PE2014001610 A PE 2014001610A PE 20142294 A1 PE20142294 A1 PE 20142294A1
Authority
PE
Peru
Prior art keywords
phenyl
indole
indazole compounds
activate ampk
hydroxyclobutyl
Prior art date
Application number
PE2014001610A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Kimberly O'keefe Cameron
Matthew Scott Dowling
David Christopher Ebner
Dilinie Prasadhini Fernando
Kevin James Filipski
Daniel Wei-Shung Kung
Esther Cheng Yin Lee
Aaron Smith
Meihua Mike Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20142294A1 publication Critical patent/PE20142294A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)

Abstract

REFERIDO A UN COMPUESTO DE LA FORMULA (I) EN DONDE X ES N O CH; R1 ES 5-OXO-4,5-DIHIDRO-1,2,4-OXADIAZOL-3-ILO , 1H-TETRAZOL-5-ILO, ENTRE OTROS; R2, R3 Y R4 SON, DE MODO INDEPENDIENTE, H, ALCOXI (C1-C6), ENTRE OTROS; R5 ES H O ALQUILO (C1-C6); L ES UN ENLACE, O, S, ENTRE OTROS; A ES FENILO, 2,3-DIHIDROBENZO[B][1,4]DIOXINILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 6-CLORO-5-(4-(1-HIDROXICICLOBUTIL)FENIL)-1H-INDOL-3-CARBOXILICO, ACIDO 6-FLUORO-5-(4-(1-HIDROXICICLOBUTIL)FENIL)-1H-INDOL-3-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UAN COMPOSICION FARMACEUTICA QUE CONTIENE DICHO COMPUESTO PARA TRATAR O PREVENIR ENFERMEDADES, CONDICIONES O TRANSTORNOS MEJORADOS POR ACTIVACION DE AMPK.
PE2014001610A 2012-04-10 2013-04-01 Compuestos de indol e indazol que activan la ampk PE20142294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261622129P 2012-04-10 2012-04-10

Publications (1)

Publication Number Publication Date
PE20142294A1 true PE20142294A1 (es) 2014-12-27

Family

ID=48237173

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001610A PE20142294A1 (es) 2012-04-10 2013-04-01 Compuestos de indol e indazol que activan la ampk

Country Status (42)

Country Link
US (2) US8889730B2 (es)
EP (1) EP2836490B1 (es)
JP (1) JP6026642B2 (es)
KR (1) KR20150002782A (es)
CN (1) CN104245688A (es)
AP (1) AP2014007983A0 (es)
AR (1) AR090633A1 (es)
AU (1) AU2013246552A1 (es)
CA (1) CA2869692C (es)
CO (1) CO7091185A2 (es)
CR (1) CR20140411A (es)
CU (1) CU20140118A7 (es)
CY (1) CY1119194T1 (es)
DK (1) DK2836490T3 (es)
DO (1) DOP2014000228A (es)
EA (1) EA028564B1 (es)
EC (2) ECSP14020545A (es)
ES (1) ES2637238T3 (es)
GT (1) GT201400215A (es)
HK (1) HK1202547A1 (es)
HR (1) HRP20171028T1 (es)
HU (1) HUE033096T2 (es)
IL (1) IL234860A0 (es)
IN (1) IN2014DN09200A (es)
LT (1) LT2836490T (es)
MD (1) MD20140109A2 (es)
ME (1) ME02729B (es)
MX (1) MX2014012330A (es)
NI (1) NI201400121A (es)
NZ (1) NZ630700A (es)
PE (1) PE20142294A1 (es)
PH (1) PH12014502280B1 (es)
PL (1) PL2836490T3 (es)
PT (1) PT2836490T (es)
RS (1) RS56290B1 (es)
SG (1) SG11201405571SA (es)
SI (1) SI2836490T1 (es)
TN (1) TN2014000420A1 (es)
TW (1) TWI465431B (es)
UY (1) UY34736A (es)
WO (2) WO2013153479A2 (es)
ZA (1) ZA201406792B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
EP3070085B1 (en) * 2013-02-04 2019-01-09 Janssen Pharmaceutica NV Flap modulators
EP2963013A4 (en) 2013-02-27 2016-09-14 Shionogi & Co INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6435923B2 (ja) * 2014-03-07 2018-12-12 Jnc株式会社 ジヒドロピラン化合物、液晶組成物および液晶表示素子
US9980948B2 (en) 2014-08-27 2018-05-29 Shionogi & Co., Ltd. Azaindole derivative having AMPK-activating activity
PT3203840T (pt) 2014-10-06 2020-10-27 Vertex Pharma Moduladores do regulador da condutância transmembranar da fibrose quística
WO2016092413A1 (en) * 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
CN107108492B (zh) * 2014-12-24 2021-03-19 北京生命科学研究所 细胞坏死抑制剂
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
WO2017011917A1 (en) * 2015-07-23 2017-01-26 Thrasos Therapeutics Inc. Methods for treating and preventing polycystic kidney diseases (pkd) using amp-activated protein kinase (ampk) modulators and activators
JPWO2017146186A1 (ja) 2016-02-26 2018-12-20 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有する５−フェニルアザインドール誘導体
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3442535B1 (en) 2016-04-15 2022-06-01 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
SG11201808878UA (en) 2016-04-15 2018-11-29 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EP3478297A1 (en) 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
KR102224550B1 (ko) * 2018-04-02 2021-03-09 울산대학교 산학협력단 신규한 에테르 화합물, 및 광 산화환원 촉매를 이용하여 활성화된 알켄 화합물로부터 에테르 화합물을 제조하는 방법
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN108572223B (zh) * 2018-04-23 2021-01-26 南京明捷生物医药检测有限公司 一种测定多肽中活性诱导物质的方法
BR112021005086A2 (pt) 2018-09-18 2021-06-08 1Globe Biomedical Co., Ltd. tratamento para doença hepática gordurosa não alcoólica
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
JP7511564B2 (ja) * 2018-12-31 2024-07-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリア機能不全を治療する方法及び配合物
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
CN112441900B (zh) * 2019-09-05 2024-07-23 浙江中科创越药业有限公司 4-联苯乙酸的制备方法
CN111333486A (zh) * 2020-04-08 2020-06-26 南京优氟医药科技有限公司 一种2-甲基-2-（4-氯苯基）-1,3-丙二醇的生产工艺
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN111423379B (zh) * 2020-05-21 2021-08-03 湖南科技大学 取代3-吲唑类Mcl-1蛋白抑制剂及制备方法和应用
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2022072397A1 (en) * 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2025021039A1 (zh) * 2023-07-21 2025-01-30 深圳众格生物科技有限公司 Ampk激动剂及其用途
WO2025045185A1 (zh) * 2023-08-31 2025-03-06 深圳众格生物科技有限公司 芳基或杂芳基取代的氨基甲酸酯类化合物及其衍生物和用途

Family Cites Families (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965855D1 (en) 1978-09-25 1983-08-18 Farlane Stuart John Mc Pharmaceutical preparations containing a mollusc extract
JP2602037B2 (ja) 1987-10-31 1997-04-23 持田製薬株式会社 １−アシル−２，３−ジヒドロ−４（１ｈ）−キノリノン−４−オキシム誘導体、その製法およびそれらを主成分とする利尿、降圧、抗浮腫および腹水除去用医薬組成物
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
JPH02264757A (ja) 1989-04-06 1990-10-29 Nippon Steel Chem Co Ltd ニトロインドール類の製造方法
US5215994A (en) 1990-09-25 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic derivatives
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
WO1993006082A1 (en) 1991-09-13 1993-04-01 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropyridines
DE4136489A1 (de) 1991-11-06 1993-05-13 Bayer Ag Neue diethylentriamin-derivate und deren verwendung zu diagnostischen und therapeutischen zwecken
EP0548553A1 (en) 1991-11-25 1993-06-30 Takeda Chemical Industries, Ltd. Optically active azole compounds, their production and use
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
WO1993020065A1 (fr) 1992-03-27 1993-10-14 Kyoto Pharmaceutical Industries, Ltd. Nouveau derive d'imidazole, son utilisation pharmaceutique, et intermediaire associe
JP3229654B2 (ja) 1992-06-05 2001-11-19 ティーディーケイ株式会社 有機ｅｌ素子用化合物および有機ｅｌ素子
WO1994001415A1 (fr) 1992-07-03 1994-01-20 Kumiai Chemical Industry Co., Ltd. Derive heterocyclique condense et desherbant
GB2271991A (en) 1992-11-02 1994-05-04 Merck Sharp & Dohme N-(2-oxo-1H-1,4-benzodiazepin-3-yl)-ureas
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
AU685881B2 (en) 1994-02-10 1998-01-29 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
HUT76923A (hu) 1994-07-27 1998-01-28 Sankyo Company Limited Muszkarinreceptorokra alloszterikus hatást kifejtő heterociklusos vegyületek
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
JPH08225535A (ja) 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
EP0717143A1 (de) 1994-12-16 1996-06-19 Lignozym GmbH Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
WO1996032379A1 (en) 1995-04-10 1996-10-17 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
AU6944696A (en) 1995-09-14 1997-04-01 Shionogi & Co., Ltd. Novel phenylacetic acid derivatives and medicinal composition containing the same
WO1997045425A1 (en) 1996-05-27 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5861398A (en) 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
JP2001518094A (ja) 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JP2002515891A (ja) 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション 新規なピペリジン含有化合物
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
CA2322162A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU9297998A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
WO2000002550A2 (en) 1998-07-08 2000-01-20 Nortran Pharmaceuticals, Inc. Acetylpiperazines for modulating sexual activity
EE04904B1 (et) 1998-07-15 2007-10-15 Teijin Limited Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
DE19842354A1 (de) 1998-09-16 2000-03-23 Bayer Ag Isothiazolcarbonsäureamide
FR2783520B1 (fr) 1998-09-21 2000-11-10 Oreal Nouveaux 4-hydroxyindoles cationiques, leur utilisation pour la teinture d'oxydation des fibres keratiniques, compositions tinctoriales et procede de teinture
WO2000028993A1 (en) 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
AR021509A1 (es) 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2001032621A1 (en) 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Novel indole derivatives and drugs containing the same as the active ingredient
CN1105722C (zh) 1999-11-12 2003-04-16 中国科学院上海药物研究所 含氮杂环基的青蒿素衍生物及其制备方法
RU2270194C2 (ru) 2000-05-22 2006-02-20 Лео Фарма А/С Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения
US6995268B2 (en) 2000-06-20 2006-02-07 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith
JP2002017387A (ja) 2000-07-06 2002-01-22 Mitsubishi Rayon Co Ltd インドール誘導体の製造法
JP2002017386A (ja) 2000-07-06 2002-01-22 Mitsubishi Rayon Co Ltd インドール−３−カルボン酸誘導体の製造法
WO2002018363A2 (en) 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
DE10046934A1 (de) 2000-09-21 2002-04-18 Consortium Elektrochem Ind Verfahren zur fermentativen Herstellung von nicht-proteinogenen L-Aminosäuren
AU2002212436A1 (en) 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
DK1381382T3 (da) 2000-11-01 2009-02-02 Merck Patent Gmbh Fremgangsmåder og præparater til behandling af öjensygdomme
US6887880B2 (en) 2000-11-20 2005-05-03 Millennium Pharmaceuticals, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof
US6387992B1 (en) 2000-11-27 2002-05-14 Ciba Specialty Chemicals Corporation Substituted 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazole UV absorbers, a process for preparation thereof and compositions stabilized therewith
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
US20040087620A1 (en) 2001-01-18 2004-05-06 Tatsuo Tsuri Terphenyl compounds bearing substituted amino groups
JPWO2002057237A1 (ja) 2001-01-22 2004-05-20 塩野義製薬株式会社 置換アミノ基を有するヘテロ３環化合物
NZ527947A (en) 2001-02-02 2005-10-28 Schering Corp 3,4-di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
CZ20032831A3 (cs) 2001-04-16 2004-03-17 Schering Corporation 3,4-Disubstituované cyklobuten-1,2-diony
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
EP1844771A3 (en) 2001-06-20 2007-11-07 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
EA005934B1 (ru) 2001-07-05 2005-08-25 Х. Лундбекк А/С Замещённые анилиновые пиперидины в качестве селективных антагонистов мсн
RU2311177C2 (ru) 2001-08-01 2007-11-27 Мерк Патент Гмбх Ингибиторы интегрина для лечения заболевания глаз
WO2003020719A1 (en) 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and use thereof
JP2005505595A (ja) 2001-10-12 2005-02-24 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物
US7666867B2 (en) 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
JP2003192716A (ja) 2001-12-27 2003-07-09 Mitsui Chemicals Inc オレフィン重合用触媒および該触媒を用いたオレフィンの重合方法
CA2477208C (en) 2002-02-21 2010-11-30 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
EP1515716A2 (en) 2002-04-03 2005-03-23 Astrazeneca AB Indole derivatives having anti-angiogenetic activity
CA2485589A1 (en) 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
WO2003099206A2 (en) 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
EP1532978A1 (en) 2002-07-09 2005-05-25 Fujisawa Pharmaceutical Co., Ltd. Remedy for urinary frequency and urinary incontinence
US6972336B2 (en) 2002-07-18 2005-12-06 Novartis Ag N-alkylation of indole derivatives
EP1546156A1 (en) 2002-08-10 2005-06-29 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
FR2846656B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT2316831E (pt) 2002-11-21 2013-06-06 Novartis Ag 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US7875605B2 (en) 2002-11-28 2011-01-25 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
AU2003296405A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
JP2006514069A (ja) 2003-01-06 2006-04-27 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子としての融合複素環式誘導体
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ATE409176T1 (de) 2003-02-21 2008-10-15 Chiesi Farma Spa 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
JP2004284998A (ja) 2003-03-24 2004-10-14 Taoka Chem Co Ltd １−アルキルインドール類の製造方法
JP2004284997A (ja) 2003-03-24 2004-10-14 Taoka Chem Co Ltd 高純度インドールカルボン酸類の製造方法
ES2338656T3 (es) 2003-04-11 2010-05-11 High Point Pharmaceuticals, Llc Uso farmaceutico de 1,2,4-triazoles fusionados.
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
EP1615637A1 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
EP1628970A2 (en) 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
EP1648881A1 (en) 2003-07-04 2006-04-26 GlaxoSmithKline S.p.A. Substituted indole ligands for the orl-1 receptor
WO2005014554A1 (en) 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
CA2535665A1 (en) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
WO2005035506A1 (ja) * 2003-10-15 2005-04-21 Ube Industries, Ltd. 新規インダゾール誘導体
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
JP4458819B2 (ja) 2003-11-13 2010-04-28 株式会社リコー アゾ置換インドール化合物及びこれを用いた光記録媒体
US7396833B2 (en) 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
WO2005097203A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Serum protein conjugates of ion channel modulating compounds and uses thereof
JP4510500B2 (ja) 2004-04-15 2010-07-21 株式会社リコー アゾ置換インドール化合物及びアゾ金属キレート化合物、並びに光記録媒体
KR20070015607A (ko) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
PT1753748E (pt) 2004-05-12 2009-08-28 Pfizer Prod Inc Derivados de prolina e a sua utilização como inibidores de dipeptidil peptidase iv
CA2568056A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
JP2008501689A (ja) 2004-06-03 2008-01-24 ブランデイス ユニヴァーシティー シンコナアルカロイドを基本構造とする二官能触媒を用いた不斉マイケル付加およびアルドール付加反応
ATE430132T1 (de) 2004-06-18 2009-05-15 Biolipox Ab Zur behandlung von entzündungen geeignete indole
CN101006053A (zh) 2004-06-18 2007-07-25 比奥里波克斯公司 用于治疗炎症的吲哚
US20080146811A1 (en) 2004-07-23 2008-06-19 Hongfeng Deng Compounds and Methods For Treatment of Thrombosis
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2580767A1 (en) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
JPWO2006038606A1 (ja) 2004-10-05 2008-05-15 塩野義製薬株式会社 ビアリール誘導体
JP2008516962A (ja) 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
JP2006131519A (ja) 2004-11-04 2006-05-25 Idemitsu Kosan Co Ltd 縮合環含有化合物及びそれを用いた有機エレクトロルミネッセンス素子
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JPWO2006051937A1 (ja) 2004-11-15 2008-05-29 塩野義製薬株式会社 ヘテロ５員環誘導体
WO2006069097A2 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
EP1844023A1 (en) 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
FR2882054B1 (fr) 2005-02-17 2007-04-13 Sanofi Aventis Sa Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
KR101048535B1 (ko) 2005-03-30 2011-07-11 주식회사 대웅제약 항진균성 트리아졸 유도체
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
AU2006247136C1 (en) 2005-05-17 2020-01-16 Bausch + Lomb Ireland Limited Compositions and methods for treatment of eye disorders
WO2006130453A1 (en) 2005-05-27 2006-12-07 Brandeis University Asymmetric aldol additions using bifunctional cinchona-alkaloid-based catalysts
WO2006130437A2 (en) 2005-05-27 2006-12-07 Brandeis University Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids
US7553964B2 (en) 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
WO2006133559A1 (en) 2005-06-14 2006-12-21 Merck Frosst Canada Ltd. Reversible inhibitors of monoamine oxidase a and b
US20080221088A1 (en) 2005-06-23 2008-09-11 Vijay Kumar Potluri 3,4-Substituted Thiazoles as Ampk Activators
BRPI0612320A2 (pt) 2005-06-27 2010-11-09 Sanofi Aventis derivados de pirazolopiridina como inibidores de receptor de cinase 1 beta-adrenégico
WO2007005785A1 (en) 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as ampk activator
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP1754483A1 (en) 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
EP1931632A4 (en) 2005-08-18 2011-05-11 Microbia Inc USEFUL INDOOR CONNECTIONS
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
MX2008005662A (es) 2005-11-03 2008-12-15 Ilypsa Inc Compuestos de azaindol y uso de los mismos como inhibidores de la fosfolipasa a2.
AU2006311765A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
CA2627089A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
WO2007058504A1 (en) 2005-11-21 2007-05-24 Lg Life Sciences, Ltd. Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same
CN1978445B (zh) 2005-12-02 2010-09-01 中国科学院上海药物研究所 一种可用作人源腺苷单核苷酸激活蛋白激酶激活剂的化合物及其制备方法和应用
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2633252A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
WO2007079173A2 (en) 2005-12-30 2007-07-12 Emergent Biosolutions Inc. Novel 2-heteroaryloxy-phenol derivatives as antibacterial agents
CN101374834B (zh) 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2647811A1 (en) 2006-03-30 2007-10-11 Asahi Kasei Pharma Corporation Substituted bicyclic derivative and use thereof
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
BRPI0710507A2 (pt) 2006-04-18 2011-08-16 Abbott Lab Antagonistas do receptor vanilóide de subtipo 1 (vr1) e usos destes
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
EP2018380B1 (en) 2006-05-19 2011-10-19 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US7846960B2 (en) 2006-05-24 2010-12-07 Eli Lilly And Company FXR agonists
CA2653424A1 (en) 2006-06-08 2007-12-13 Ube Industries, Ltd. Novel indazole derivative having spiro ring structure in side chain
EP2046741B1 (en) 2006-07-03 2012-10-31 Proximagen Ltd. Indoles as 5-ht6 modulators
FR2903695B1 (fr) 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100826108B1 (ko) 2006-08-04 2008-04-29 한국화학연구원 퓨란-2-카복실산 유도체 및 그의 제조 방법
WO2008019357A2 (en) 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
JP2008106037A (ja) 2006-09-29 2008-05-08 Osaka Prefecture Univ インドール化合物の製造方法およびインドール化合物
WO2008054748A2 (en) 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN101541809A (zh) 2006-11-29 2009-09-23 辉瑞产品公司 螺环酮乙酰基-CoA羧化酶抑制剂
CN101616587A (zh) 2006-12-05 2009-12-30 孙仲铭 吲唑化合物
WO2008072850A1 (en) 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
ES2396160T3 (es) 2006-12-14 2013-02-19 Bayer Intellectual Property Gmbh Derivados de DIHIDROPIRIDINA que utiliza como inhibidores de la proteina quinasa
WO2008077079A1 (en) 2006-12-18 2008-06-26 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR20090101905A (ko) 2006-12-22 2009-09-29 노파르티스 아게 인돌-４-일-피리미디닐-일-아민 유도체 및 사이클린 의존성 키나제 억제제로서의 그의 용도
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US7999001B2 (en) 2007-01-15 2011-08-16 The United States Of America As Represented By The Secretary Of The Army Antiviral compounds and methods of using thereof
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
JP2008179567A (ja) 2007-01-25 2008-08-07 Toray Ind Inc ピラジン誘導体を有効成分とする抗がん剤
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
AU2008216382A1 (en) 2007-02-12 2008-08-21 Array Biopharma, Inc. Novel inhibitors hepatitis C virus replication
JP5107589B2 (ja) 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
JP2008208074A (ja) 2007-02-27 2008-09-11 Toray Ind Inc ピラジン誘導体を有効成分とする抗がん剤
JP2008222576A (ja) 2007-03-09 2008-09-25 Japan Enviro Chemicals Ltd インドール化合物の製造方法
WO2008110863A1 (en) 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2142545A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
KR20080099174A (ko) 2007-05-07 2008-11-12 주식회사 머젠스 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2009019446A1 (en) 2007-08-03 2009-02-12 Betagenon Ab Compounds useful as medicaments
KR20090016804A (ko) 2007-08-13 2009-02-18 주식회사 티지 바이오텍 신규 벤질에스테르계 화합물 및 이를 유효성분으로함유하는 비만, 당뇨 및 고지혈증의 예방 및 치료용 조성물
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
CN101821252A (zh) 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
PE20090995A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
EP2215075B1 (en) 2007-10-26 2013-12-11 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp inhibitors
US20090124680A1 (en) 2007-10-31 2009-05-14 Mazence Inc. Use of prodrug composition containing naphthoquinone-based compound for manufacture of medicament for treatment or prevention of diseases involving metabolic syndrome
MX2010005298A (es) 2007-11-16 2010-06-30 Rigel Pharmaceuticals Inc Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
WO2009064852A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US20100311965A1 (en) 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
CN101925748B (zh) 2008-01-31 2013-01-02 国立大学法人横滨国立大学 流体机械
MY158994A (en) * 2008-02-04 2016-11-30 Mercury Therapeutics Inc Ampk modulators
WO2009115874A2 (en) 2008-03-17 2009-09-24 Matrix Laboratories Ltd. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
KR101209373B1 (ko) 2008-03-20 2012-12-06 에프. 호프만-라 로슈 아게 피롤리디닐 유도체 및 이의 용도
WO2009120783A1 (en) 2008-03-25 2009-10-01 The Johns Hopkins University High affinity inhibitors of hepatitis c virus ns3/4a protease
WO2009118370A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2721025C (en) 2008-04-11 2016-07-26 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
AU2009240643B2 (en) 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
BRPI0910832B8 (pt) 2008-05-05 2021-05-25 Merck Patent Ges Mit Beschraenkter Haftung derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CA2724774C (en) 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2724603A1 (en) 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
MX2010013577A (es) 2008-06-16 2010-12-21 Merck Patent Gmbh Derivados de quinoxalindiona.
US8217028B2 (en) 2008-06-20 2012-07-10 Glaxo Group Limited 1,2,4-oxadiazole indole compounds
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
US20110190324A1 (en) 2008-07-16 2011-08-04 Edward Leung Methods of treating atherosclerosis
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
CA2736472A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
WO2010036910A1 (en) 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741300A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010056041A2 (ko) 2008-11-13 2010-05-20 주식회사 머젠스 허혈 또는 허혈 재관류에 의해 유발되는 심장질환의 치료 및 예방을 위한 약제 조성물
RU2528406C2 (ru) 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
EA201170828A1 (ru) 2008-12-18 2011-12-30 Мерк Сероно С.А. Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US20120122889A1 (en) 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2010088392A1 (en) 2009-01-28 2010-08-05 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
US20100210682A1 (en) 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
WO2010103438A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
AU2010222589B2 (en) 2009-03-11 2012-08-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
JP2012520868A (ja) 2009-03-20 2012-09-10 ファイザー・インク ３−オキサ−７−アザビシクロ［３．３．１］ノナン
CN102361878A (zh) 2009-03-24 2012-02-22 住友化学株式会社 用于制备硼酸酯化合物的方法
EP2607348B8 (en) 2009-03-31 2021-04-21 Renascience Inc. Plasminogen Activator Inhibitor-1 Inhibitor
WO2010118009A1 (en) 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
WO2010128425A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
JP2012526096A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
JP2012528847A (ja) 2009-06-05 2012-11-15 ファイザー・インク Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体
SG177558A1 (en) 2009-07-08 2012-02-28 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
EP2459533A4 (en) 2009-07-30 2013-01-16 Univ Singapore SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
WO2011032320A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
CN102803269B (zh) 2009-12-29 2016-01-13 珀科赛尔 Ampk的噻吩并[2,3-b]嘧啶二酮活化剂及其治疗用途
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
US8344137B2 (en) 2010-04-14 2013-01-01 Hoffman-La Roche Inc. 3,3-dimethyl tetrahydroquinoline derivatives
JP2013525466A (ja) 2010-05-05 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｍｐｋのアクチベーターとして用いられるピロロ［３，２−ｄ］ピリミジン−３−イル誘導体
US8592594B2 (en) 2010-07-02 2013-11-26 Hoffmann-La Roche Inc. Tetrahydro-quinoline derivatives
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
KR101190141B1 (ko) 2010-08-24 2012-10-12 서울대학교산학협력단 Ａｍｐｋ를 활성화시키는 화합물을 함유하는 약학조성물
WO2012027548A1 (en) 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
JP2013230986A (ja) 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
ES2573412T3 (es) 2010-09-10 2016-06-07 Shionogi & Co., Ltd. Derivado de imidazol de heteroanillo fusionado que tiene efecto de AMPK (activacion de proteina cinasa activada por monofosfato de adenosina)
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
US8546427B2 (en) 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
US8809369B2 (en) 2011-01-26 2014-08-19 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
JP2014507452A (ja) 2011-03-07 2014-03-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー キノリン誘導体
US20130345243A1 (en) 2011-03-07 2013-12-26 Glaxosmithkline Llc 1h-pyrollo[3,2-d]pyrimidinedione derivatives
JP5855253B2 (ja) 2011-08-12 2016-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インダゾール化合物、組成物及び使用方法
MX351287B (es) 2012-02-21 2017-10-09 Acraf Compuestos de 1h-indazol-3-carboxamida como inhibidores de glucogeno sintasa quinasa 3 beta.

Also Published As

Publication number Publication date
AR090633A1 (es) 2014-11-26
IL234860A0 (en) 2014-12-31
ME02729B (me) 2017-10-20
LT2836490T (lt) 2017-08-10
CO7091185A2 (es) 2014-10-21
MX2014012330A (es) 2015-01-12
EP2836490B1 (en) 2017-06-14
AU2013246552A1 (en) 2014-09-25
EA028564B1 (ru) 2017-12-29
ECSP14026271A (es) 2015-11-30
JP6026642B2 (ja) 2016-11-16
NZ630700A (en) 2015-11-27
PT2836490T (pt) 2017-08-23
EA201491592A1 (ru) 2015-03-31
NI201400121A (es) 2015-03-05
PH12014502280A1 (en) 2014-12-15
HRP20171028T1 (hr) 2017-10-06
HUE033096T2 (en) 2017-11-28
DOP2014000228A (es) 2014-11-30
IN2014DN09200A (es) 2015-07-10
RS56290B1 (sr) 2017-12-29
US20130267493A1 (en) 2013-10-10
TWI465431B (zh) 2014-12-21
DK2836490T3 (en) 2017-07-31
SI2836490T1 (sl) 2017-08-31
ECSP14020545A (es) 2017-07-31
WO2014140704A1 (en) 2014-09-18
TW201402547A (zh) 2014-01-16
ES2637238T3 (es) 2017-10-11
SG11201405571SA (en) 2014-10-30
MD20140109A2 (ro) 2015-02-28
CA2869692C (en) 2016-08-02
WO2013153479A2 (en) 2013-10-17
JP2015512931A (ja) 2015-04-30
CU20140118A7 (es) 2014-11-27
US8889730B2 (en) 2014-11-18
HK1202547A1 (en) 2015-10-02
GT201400215A (es) 2015-10-15
EP2836490A2 (en) 2015-02-18
US20150038484A1 (en) 2015-02-05
PL2836490T3 (pl) 2017-10-31
CR20140411A (es) 2014-10-14
TN2014000420A1 (fr) 2016-03-30
CN104245688A (zh) 2014-12-24
CA2869692A1 (en) 2013-10-17
UY34736A (es) 2013-11-29
PH12014502280B1 (en) 2014-12-15
AP2014007983A0 (en) 2014-10-31
CY1119194T1 (el) 2018-02-14
WO2013153479A3 (en) 2013-12-05
ZA201406792B (en) 2016-01-27
KR20150002782A (ko) 2015-01-07

Similar Documents

Publication Publication Date Title
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
PE20142282A1 (es) Nuevos derivados de aril-quinolina
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
EA201000024A1 (ru) Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
GEP20146197B (en) New compounds
SV2009003233A (es) Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
PE20091425A1 (es) Derivados de aminotiazol
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
ATE473221T1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität

Legal Events

Date Code Title Description
FD Application declared void or lapsed